NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features. The MMRD-GREEN trial
PET Response Adapted Design Comparing ABVD +/- ISRT with A2VD +/- ISRT in Patients with Stage IA/IIA Hodgkin Lymphoma (RADAR)
Neoadjuvant Platform Trial in Surgically Resectable NSCLC
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MYELOMATCH) for the NCI myeloMATCH clinical trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
NEEDS: NEoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed)
CCTG is still accepting members for our Equity, Diversity, Inclusivity, Indigenization, Accessibility (EDIIA) Working Groups as we strive to create a more equitable, diverse, inclusive, accessible, and culturally safe community for our network and for our patient participants.
The CCTG SC28 SEAMLESS study is now open in Canada for anyone who has completed their primary cancer treatment, to learn mindfulness meditation on an app and see if it helps to improve stress and well being
"People who have had cancer may have multiple unmet psychosocial needs after the completion of their primary treatment, and for the first 5 years of surveillance and follow-up. Survivors often report feeling “lost in transition” as they shift back to their previous lives at home and in the workplace," says study chair Dr. Linda Ellen Carlson, Tom Baker Cancer Centre.
The CCTG HD12 trial is the second study in the RADAR international trial and has recently opened in Canada. Researchers will compare the usual treatment for Hodgkin lymphoma, with a new treatment that takes the standard combination drug treatment replacing one of the drugs with brentuximab vedotin that may be more effective and cause fewer side effects for patients.
